Research programme: anti-HIV therapies - Isis/ImQuest

Alternative Names: Combination topical microbicide product - ImQuest Biosciences; IQP-0831; ISIS-5320; NSC 665353

Latest Information Update: 28 Jul 2020

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Isis Pharmaceuticals
Developer ImQuest Life Sciences; Isis Pharmaceuticals
Class Antivirals; Oligodeoxyribonucleotides; Thionucleotides
Mechanism of Action HIV envelope protein gp120 inhibitors; HIV fusion inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

20 Jul 2020 ImQuest Life Sciences has been acquired by Cytocom
29 Mar 2012 No development reported - Preclinical for HIV infections (prevention) in USA (Topical)
06 Aug 2008 This programme is still in active preclinical development

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com